Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not all patients equally benefit from immunotherapy. The use of cytotoxic drugs is practically inevitable to treat advanced cancers and metastases. The repertoire of cytotoxics includes 80 products that principally target nucleic acids or…
NAR Cancer Template
Write in a clean editor, then format for NAR Cancer in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the NAR Cancer format
NAR Cancer is a peer-reviewed journal published by Oxford University Press, covering DNA Repair Mechanisms, RNA modifications and cancer, Cancer Genomics and Diagnostics.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', NAR Cancer, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — NAR Cancer has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | DNA Repair Mechanisms RNA modifications and cancer Cancer Genomics and Diagnostics RNA Research and Splicing PARP inhibition in cancer therapy |
| ISSN | 2632-8674 |
| Citation impact (2-yr) | 5.32 |
| h-index | 34 |
| i10-index | 159 |
| Total citations | 5,092 |
| Article processing charge | $2,225 |
| Open access | Yes |
| Top institutions publishing here | Centre National de la Recherche Scientifique |
| Journal website | academic.oup.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in NAR Cancer per year
Citation impact of NAR Cancer by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in NAR Cancer
Single-stranded DNA (ssDNA) forms continuously during DNA replication and is an important intermediate during recombination-mediated repair of damaged DNA. Replication protein A (RPA) is the major eukaryotic ssDNA-binding protein. As such, RPA protects the transiently formed ssDNA from nucleolytic degradation and serves as a physical platform for the recruitment of DNA damage response factors. Prominent…
Recent epitranscriptomics studies unravelled that ribosomal RNA (rRNA) 2'O-methylation is an additional layer of gene expression regulation highlighting the ribosome as a novel actor of translation control. However, this major finding lies on evidences coming mainly, if not exclusively, from cellular models. Using the innovative next-generation RiboMeth-seq technology, we established the first rRNA 2'O-methylation landscape…
Regulation of homologous recombination (HR) is central for cancer prevention. However, too little HR can increase cancer incidence, whereas too much HR can drive cancer resistance to therapy. Importantly, therapeutics targeting HR deficiency have demonstrated a profound efficacy in the clinic improving patient outcomes, particularly for breast and ovarian cancer. RAD51 is central to DNA…
Abstract Radiation-induced foci (RIF) are nuclear puncta visualized by immunostaining of proteins that regulate DNA double-strand break (DSB) repair after exposure to ionizing radiation. RIF are a standard metric for measuring DSB formation and repair in clinical, environmental and space radiobiology. The time course and dose dependence of their formation has great potential to predict…